| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Pretreatment with 27-Deoxyactein at concentrations of 1, 5, and 10 μM for 24 hours significantly attenuated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced cytotoxicity in MC3T3-E1 osteoblastic cells, as evidenced by increased cell viability compared to TCDD-only treated cells. [1]
27-Deoxyactein dose-dependently reduced TCDD-induced reactive oxygen species (ROS) generation in MC3T3-E1 cells, with the highest concentration (10 μM) showing the most potent ROS scavenging effect. [1] TCDD-induced upregulation of pro-inflammatory cytokines (TNF-α, IL-6) and cyclooxygenase-2 (COX-2) mRNA expression was significantly inhibited by 27-Deoxyactein pretreatment, as determined by real-time PCR. [1] 27-Deoxyactein reversed TCDD-mediated downregulation of osteogenic markers (alkaline phosphatase, osteocalcin) and upregulation of apoptotic proteins (Bax/Bcl-2 ratio, cleaved caspase-3) in MC3T3-E1 cells, as confirmed by Western blot analysis. [1] |
|---|---|
| Cell Assay |
MC3T3-E1 cells were cultured in appropriate medium supplemented with fetal bovine serum and antibiotics, maintained in a humidified incubator with 5% CO2 at 37°C. [1]
For cytotoxicity assay: Cells were seeded in 96-well plates, allowed to adhere overnight, pretreated with 27-Deoxyactein (1, 5, 10 μM) for 24 hours, then exposed to TCDD (10 nM) for another 24 hours; cell viability was assessed using a colorimetric assay with a specific reagent, and absorbance was measured at a designated wavelength. [1] For ROS detection: Cells were seeded in 6-well plates, pretreated with 27-Deoxyactein and exposed to TCDD as described, then loaded with a fluorescent probe for 30 minutes at 37°C; fluorescence intensity was detected using a flow cytometer to quantify ROS levels. [1] For Western blot: Cells were harvested after treatment, lysed in lysis buffer containing protease inhibitors, protein concentrations were determined, equal amounts of protein were separated by SDS-PAGE, transferred to membranes, incubated with primary antibodies against target proteins (Bax, Bcl-2, cleaved caspase-3, osteogenic markers) and secondary antibodies, then visualized using an enhanced chemiluminescence system. [1] For real-time PCR: Total RNA was extracted from treated cells, reverse-transcribed into cDNA, PCR amplification was performed with specific primers for TNF-α, IL-6, COX-2, and housekeeping gene, and relative mRNA expression levels were calculated using the comparative Ct method. [1] |
| References |
|
| Additional Infomation |
26-Deoxy-Acetin is a triterpenoid compound with the function of a metabolite.
26-Deoxy-Acetin has been reported to exist in Actaea elata, Actaea cimicifuga, and Actaea racemosa, with relevant data. See also: Actaea cimicifuga (partial). 27-Deoxy-Acetin is a triterpenoid glycoside isolated from Actaea cimicifuga. [2] The absolute configuration of 27-Deoxy-Acetin has been determined, and its structure has been resolved using spectroscopic methods including one-dimensional and two-dimensional nuclear magnetic resonance, mass spectrometry, and chemical derivatization. [2] Nomenclature confusion associated with 27-Deoxy-Acetin has been resolved, and it has been distinguished from 26-Deoxy-Acetin based on structural differences in its side chains. [2] The protective effect of 27-deoxyacin against TCDD-induced MC3T3-E1 cell damage is related to its antioxidant, anti-inflammatory, anti-apoptotic, and osteoprotective activities. [1] |
| Molecular Formula |
C37H56O10
|
|---|---|
| Molecular Weight |
660.8346
|
| Exact Mass |
660.387
|
| CAS # |
264624-38-6
|
| PubChem CID |
10974362
|
| Appearance |
White to off-white solid powder
|
| Density |
1.32±0.1 g/cm3
|
| Melting Point |
258-260 °C
|
| LogP |
3.71
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
47
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
C[C@@H]1C[C@@]2([C@H]3[C@](O3)(CO2)C)O[C@@H]4[C@H]1[C@]5([C@@H](C[C@@]67C[C@@]68CC[C@@H](C([C@@H]8CC[C@H]7[C@@]5(C4)C)(C)C)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)OC(=O)C)C
|
| InChi Key |
GCMGJWLOGKSUGX-RBKCHLQLSA-N
|
| InChi Code |
InChI=1S/C37H56O10/c1-18-12-37(30-33(6,47-30)17-43-37)46-21-13-32(5)23-9-8-22-31(3,4)24(45-29-28(41)27(40)20(39)15-42-29)10-11-35(22)16-36(23,35)14-25(44-19(2)38)34(32,7)26(18)21/h18,20-30,39-41H,8-17H2,1-7H3/t18-,20-,21+,22+,23+,24+,25-,26+,27+,28-,29+,30-,32+,33-,34-,35-,36+,37+/m1/s1
|
| Chemical Name |
[(1R,1'R,3'R,4S,4'R,5R,5'R,6'R,10'S,12'S,13'S,16'R,18'S,21'R)-1,4',6',12',17',17'-hexamethyl-18'-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~151.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5132 mL | 7.5662 mL | 15.1325 mL | |
| 5 mM | 0.3026 mL | 1.5132 mL | 3.0265 mL | |
| 10 mM | 0.1513 mL | 0.7566 mL | 1.5132 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
